Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis

Lee, Haur Yueh; Lie, Denny; Lim, KokBin; Thirumoorthy, T; Pang, Shiu Ming

doi:10.1007/s00198-008-0677-0

Cited by 36 publications

(20 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…but systemic application of strontium might be related to potential adverse reactions, such as toxic epidermal necrolysis [39], drug rash with eosinophilia and systemic symptoms (DRESS) syndrome [40,41]. Thus, local application of strontium might be an alternative method to enhance implant osseointegration, and to avoid the potential adverse reactions.…”

Section: Tablementioning

confidence: 97%

The effect of strontium-substituted hydroxyapatite coating on implant fixation in ovariectomized rats

Li¹,

Li²,

Zhu³

et al. 2010

Biomaterials

262

181

View full text Add to dashboard Cite

Section: Tablementioning

confidence: 97%

The effect of strontium-substituted hydroxyapatite coating on implant fixation in ovariectomized rats

Li¹,

Li²,

Zhu³

et al. 2010

Biomaterials

262

181

View full text Add to dashboard Cite

“…Ranelic acid serves as a carrier for strontium ranelate, but the biologic activity and toxicity of ranelic acid are unclear. Some side effects of ranelic acid, such as toxic epidermal necrolysis, have been reported [17] . Researchers remain uncertain if these side-effects are caused by strontium or ranelic acid.…”

Section: Introductionmentioning

confidence: 99%

Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway

Zhang

et al. 2012

Acta Pharmacol Sin

View full text Add to dashboard Cite

Aim: To evaluate the protective effects of strontium fructose 1,6-diphosphate (FDP-Sr), a novel strontium salt that combined fructose 1,6-diphosphate (FDP) with strontium, on bone in an ovariectomy-induced model of bone loss. Methods: Eighty female Sprague-Dawley rats were ovariectomized (OVX) or sham-operated. Three months later, the rats were assigned to six groups (10 for each): sham-operated, OVX control, OVX+FDP-Sr (110, 220, or 440 mg/kg), or OVX+strontium ranelate (SR, 180 mg/kg). Drugs were administered orally for 3 months. When the treatment was terminated, the following parameters were assessed: bone mineral density (BMD), the biomechanical properties of the femur and lumbar vertebrae, trabecular histomorphology, serum phosphorus, calcium, bone-specific alkaline phosphatase (B-ALP), tartrate-resistant acid phosphatase 5b (TRACP5b), N-telopeptide of type I collagen (NTx) and a series of markers for oxidative stress. Receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG) levels in serum were measured using ELISA and their gene expression levels in the bone were measured using R-T PCR. Results: Treatment with FDP-Sr (220 or 440 mg/kg) or SR (180 mg/kg) significantly increased the BMD and improved the bone microarchitecture and bone strength in OVX rats. The treatments also decreased in the levels of H 2 O 2 and MDA, restored the CAT level in serum and bone marrow, increased the serum B-ALP and decreased NTx and TRACP 5b in OVX rats. Treatment with FDP-Sr decreased the RANKL level, and increased the OPG level in serum in a dose-dependent manner. It also significantly down-regulated the RANKL expression and up-regulated OPG expression in bone marrow. Conclusion: FDP-Sr may be an effectve treatment for postmenopausal osteoporosis that acts, in part, via a decrease in osteoclastogenesis through the OPG\RANKL\RANK pathway.Keywords: osteoporosis; ovariectomy; strontium fructose 1,6-diphosphate; strontium ranelate; osteoprotegerin (OPG); receptor activator of NF-κB ligand (RANKL); bone mineral density; tartrate-resistant acid phosphatase 5 (TRACP5); N-telopeptide of type I collagen (NTx)

show abstract

“…Another case of a generalized cutaneous eruption [42] with no fever with strontium ranelate resolved completely after withdrawal of treatment. Hypersensitivity syndromes, such as DRESS [43,44] and TEN [45] have also been reported. However, they are very rare (<1 case per 10,000), and with early recognition and appropriate management, the prognosis can be improved [40,46].…”

Section: Cutaneous Adverse Reactions To Antiosteoporotic Agentsmentioning

confidence: 95%

Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity

et al. 2009

View full text Add to dashboard Cite

show abstract

Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis

Cited by 36 publications

References 3 publications

The effect of strontium-substituted hydroxyapatite coating on implant fixation in ovariectomized rats

The effect of strontium-substituted hydroxyapatite coating on implant fixation in ovariectomized rats

Strontium fructose 1,6-diphosphate prevents bone loss in a rat model of postmenopausal osteoporosis via the OPG/RANKL/RANK pathway

Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity

Contact Info

Product

Resources

About